An Australian-led international research collaboration has delivered a promising breakthrough in the quest to better ...
Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, ...
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced the publication of ...
There's a lot to love about coffee. From its delicious taste to its utterly intoxicating aroma, and the social ritual of ...
Why is autism more common in men? A new study identifies the MDGA1 gene mutation and the protective role of estrogen in females.
One of the family's twins was diagnosed with Sanfilippo syndrome at 18 months.An Australian-led international research ...
From burnout to brain fog to unrelenting fatigue, millions are experiencing the hidden neurological effects of chronic stress. A rece ...
Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 ...
The next surprise was that human organoids just kept growing. Mouse organoids were done with making neurons within nine days.
Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND, April 7, 2026 /PRNewswire/ -- NeuroTherapia, Inc., a clinical-stage company focused on developing oral ...
The field of neuroplasticity is increasingly exploring the non-neuronal components that shape synaptic, cellular, and circuit-level adaptation in the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results